AstraZeneca Could Seek New Indication For Iressa In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
The company announces withdrawal of European Marketing Authorisation Application for gefitinib in treatment of non-small cell lung cancer. FDA is expected to provide an update on the status of Iressa's subpart H approval in January or February.
You may also be interested in...
AstraZeneca Gives Iressa Another Go In The EU
Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.
AstraZeneca Gives Iressa Another Go In The EU
Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.
Iressa Advisory Committee Will Not Vote On Oncologic’s Status – AstraZeneca
FDA will not make a regulatory decision on Iressa until survival study data have been fully analyzed, AstraZeneca says; the company expects to complete its data analysis by July. AstraZeneca will present “top-line” data from the ISEL survival study at the March 4 Oncologic Drugs Advisory Committee meeting.